CKD and cardiometabolic
GLP-1 drugs in CKD: an endocrinologist's guide to starting low and staying on
A CJASN How I Treat case argues the barrier to GLP-1 receptor agonists in CKD is putting them into practice, not the evidence. It lays out titration, lab checks, insulin cuts and how to protect muscle.